What the FDA labels say about taking them together
Glipizide and pramlintide
Glipizide's FDA label of January 8, 2026 names pramlintide in its drug interactions section; pramlintide's label does not name glipizide itself but warns about its class (Sulfonylureas). The glipizide label: “… disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory …”
Check it at the source: the glipizide FDA label on DailyMed (effective January 8, 2026, Aurobindo Pharma Limited); the pramlintide FDA label on DailyMed (effective December 18, 2019, AstraZeneca Pharmaceuticals LP).
What does the glipizide label say about pramlintide?
Glipizide label, drug interactionsThe following are examples of medication that may increase the glucose lowering effect of glipizide extended-release tablets, increase the susceptibility to and/or intensity of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol, probenecid, coumarins, voriconazole, H2 receptor antagonists, and quinolones.
Source: FDA drug label (Glucotrol Xl, NDA020329), Roerig, effective July 21, 2026 (SPL set eed99b60-d043-4249-9b2a-f05e46fb588d), via openFDA
Source: FDA drug label (Glipizide), Aurobindo Pharma Limited, effective January 8, 2026 (SPL set 84794a52-b717-488c-8533-6425c83d405f), via openFDA; the full label on DailyMed
What does the pramlintide label say about glipizide?
Pramlintide's label does not name glipizide itself; it warns about its class (Sulfonylureas):
Pramlintide label, warnings and precautionsThe addition of any anti-diabetic medication, such as SYMLIN, to an existing regimen of one or more anti-diabetic medications (e.g., sulfonylurea), or other medications that can increase the risk of hypoglycemia may necessitate further insulin dose adjustments and particularly close monitoring of blood glucose.
Source: FDA drug label (SymlinPen), AstraZeneca Pharmaceuticals LP, effective December 18, 2019 (SPL set 4aea30ff-eb0d-45c1-b114-3127966328ff), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Glipizide | Pramlintide | |
|---|---|---|
| Labeled for | Type 2 diabetes | Type 2 diabetes, Type 1 diabetes |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0339 per tablet 5 mg tablet | n/a |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once